Background: Management options for cystic echinococcosis (CE) remain a serious problem. The main aim of this study was to examine the selection and complications of treatment applied in patients with CE. The second aim was to evaluate the mortality rate and causative factors.
Introduction
Cystic echinococcosis (CE) is a chronic, complex and neglected zoonotic disease caused by the larval stage (metacestode) of Echinococcus granulosus. CE occurs worldwide, but it is endemic in central Asia, northern and eastern Africa, Australia, South America and the Mediterranean Basin. [1] [2] [3] In humans, it may result in a wide spectrum of clinical manifestations, ranging from asymptomatic infection to fatal disease. 4 The clinical management of CE is complex and fundamentally based on three pillars -surgical, pharmacological and percutaneous treatment, which are sometimes administered as complementary treatments. 5, 6 Treatment should be defined according to the characteristics, location and type of cysts. Available medical/surgical expertise and equipment, and adherence of patients to long-term monitoring. Surgery is one of the most commonly used-percutaneous treatment, such as puncture-aspiration-injection-respiration (PAIR), may possibly replace surgery in specific cases. [7] [8] [9] Other techniques, such as modified catheterization technique (MoCaT), modified percutaneous evacuation (PEVAC), immunological or chemo-radioisotope therapies and radiofrequency thermal ablation (RFA) will merit more attention in the future. 8 Anthelmintics, mainly benzimidazoles alone or in combination with other drugs, such as praziquantel, have so far been reserved for non-operated patients and have had a secondary role, 10, 11 in reducing the risk of anaphylaxis, dissemination and/or post-operative recurrence. 12 However, in select patients, the option of 'watch and wait' is being validated. 13 Therefore, despite advances in surgical techniques, the use of chemotherapy and others treatments, and attempts made by WHO, the management of CE disease remains a major problem. 14 Today, there is still no consensus on the management of CE, 15 and consequently, the 'best' treatment is still a subject of debate. 13, 16 As such, it is essential to develop clinical studies comparing treatments in homogeneous groups of patients. However, there are a lot of important difficulties in developing prospective clinical assays for CE, such as the long-term evolution of this infection, the heterogenicity of patients and cysts, and the absence of clinical tools for detecting infection or relapse in early stages of infection. Thus, based on retrospective work, it will be essential to examine the evolution of CE patients with different types of treatment. The first aim of this study was to examine the treatment applied in a cohort of patients with CE, the factors involved in the treatment selection and the treatment complications. The second aim was to evaluate the mortality rate and the causative factors.
Material and methods
The design of this study was a descriptive longitudinalretrospective study that was performed in two phases. First, in this cohort, the treatment applied, and the factors involved in the treatment selection and the treatment complications, are described. All patients diagnosed with CE were reviewed according to the ICD-9 (code 122·0 to 122·9) criteria who were admitted to CAUSA between January 1998 and December 2015. CAUSA is a tertiary care hospital that covers an area of 12 350 km, 2 and it accommodated 342 459 inhabitants in 2014 (National Institute of Statistics (INE); http://www.ine.es/) 17 and is located in western Spain. Clinical and epidemiological data were collected after review of medical records. Diagnosis and classification of CE were assessed according to the criteria proposed by the World Health Organization Informal Working Group on Echinococcosis for CE. 15 Surgical complications were defined as any deviation from the normal postoperative course. 18 Hypertransaminasemia was defined as having serum transaminase levels at a value greater than five times the upper limit of normal (UI/L). Second, the mortality rate in patients who attended follow-up at this hospital and the causative factors was evaluated. Follow-ups were defined with two or more clinical controls. Patients with duplicate records, without followup or with missing data were excluded from the study.
Additionally, the sample was stratified according to treatment strategy performed in these patients: 'surgery alone', 'drugs alone', 'surgery and drugs', and 'watch and wait'. Criteria selection for each strategy depends on practitioner's choice as there are no guidelines for treatment in this center.
Statistical analysis
The results were expressed as percentages for categorical variables and as the mean and SD for continuous variables. To perform bivariate analysis, a chi-square test was used to compare the association between categorical variables, such as clinical and demographics variables, and the measured outcome was expressed as the odds ratio (OR), together with the 95% CI for OR. Continuous variables were compared with Student's t-test, analysis of variance (ANOVA) or Mann-Whitney test for two groups, depending on their normal or non-normal distribution, and least significant difference (LSD) post hoc test. Additionally, the logistic regression model was applied to perform multivariate analysis of variables that influenced mortality of the cohort, estimating the parameter B, standard error (S.E.), and statistical significance with the Wald test and the estimation of the OR (Exp (B)) with 95% CI. Multi-correspondence analysis was performed to help interpret the relationships between the categories of the variables. Survival rates were analyzed by a Kaplan-Meier method. A p-value <0.05 was considered as a statistically significant difference. All data were analyzed with SPSS Statistics 23 (Statistical Package for the Social Sciences).
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Results
A total of 571 patients with new CE-related diagnosis codes 122.0 to 122.9 were registered in CAUSA between January 1998 and December 2015. Of these patients, 80 patients with missing data were excluded from the study. Thus, 491 patients with new CE diagnosis were included in the study, and the patient data stratified according to the therapeutic strategy performed are shown in Table 1 : 166 (33.8%) patients received only surgery, V. Velasco-Tirado et al. A total of 288 patients were male (58.7%), the mean age (±SD) was 59.5±20.4 years, and adding the above-mentioned groups, a total of 360 (73.3%) patients received medical and/or surgical treatment v. 131 (26.7%) patients decided on the watch and wait option. The temporal evolution of the different strategies implemented in the cohort during the study period is presented in Figure 1 . There are significant differences in the percentage distribution over the study period between different treatment groups, and thus, while surgery alone or anthelmintics only were the more common treatment strategies at the start of the cohort study, the combination of both therapies was the most frequent treatment strategy at the end of the cohort study (p<0.001).
The mortality rate was analyzed in 247 (50.3%) patients who attended follow-up this hospital.
Surgery treatment
A total of 342 (69.6%) were treated by any surgical method: 166 (48.5%) received surgery as the only treatment and 176 (51.5%) received surgery in combination with anthelmintics. Variables associated with an indication of surgical intervention of CE were location of CE, which was more frequent in thoracic cyst than hepatic locations [62/69 (89.9%) v. 274/410 (66.8%)], (OR=4.46, 95% CI, 1.99-9.99; p<0.001). The main surgical techniques are shown in Table 2 .
After surgery, 65/342 (19.0%) patients had complications, with the most frequent being postoperative fistula (17); these complications are shown in Figure 2 . Between the variables associated with surgical complications, the location of the cyst was the most prominent. The authors found less postoperative complications in lung cysts [7/ Postoperative complications were not associated with age, sex, comorbidity, or any immunodeficiency. Among the surgically treated patients, seven (2%) patients died from postoperative complications-six from sepsis and one from massive hemoptysis. A higher mortality rate was detected depending on the age (7/7 deaths involved patients older than 60 years, (Figure 2) , which occurred more frequently in patients with albendazole and praziquantel than in patients with albendazole alone [9/70 (12.9%) v. 6/123 (4.9%)] (OR=2.87, 95% CI 1.01-8.45, p=0.047). The most frequently detected complications were digestive intolerance (8) and hypertransaminasemia (6) (Figure 2 ). All cases were resolved after drug discontinuation. These complications were not related to age, sex or comorbidity (p>0.05). 
Watch and wait strategy

Overall survival and mortality
Of the total cohort, only 247 (50.3%) patients attended followup this hospital with two or more revisions, with a mean (±SD) duration of 3.36±3.50 years. The Kaplan-Meier curve of the study period is shown in Figure 3 , which was associated with age, immunosuppression and comorbidity (p<0.001) and was not associated with gender, clinical diagnosis, complications or recurrences (p>0.05). Figure 2 . Complications associated to medical and surgical treatment. *Others: one of each septic shock, intestinal ischemia, hypernatremia, nosocomial pneumonia, acute pulmonary edema, anemia, hemoperitoneum, hemothorax, splenic bleeding, incisional wound, multiorgan failure.
Surgical treatament Medical treatment
Transactions of the Royal Society of Tropical Medicine and Hygiene
Eighty (16.3%) patients died along the study, 14 of them (2.9%) were directly caused by CE disease or other complications (Table 1 ). Other causes of mortality not related to echinococcosis were as follows: cancer (26, 32%), cardiovascular (17, 21%), other non-related infectious diseases (13, 16%) and other non-specified complications. First, the overall survival/mortality rate in the cohort (all-cause mortality), was analyzed 80 exitus.
Bivariate analysis showed that the variables significantly (p<0.05) associated with higher mortality were age, immunosuppression, comorbidity, number of liver segments and treatment strategy (Table 3) .
Multivariate logistic regression analysis confirmed that age is a risk factor (p=0.003), and the clinical variables that most significantly influenced the overall cohort mortality were the presence of comorbidity [Exp(B)=7.06; 95%CI, 
Discussion
Over decades the clinical management of echinococcosis has evolved without adequate evaluation of efficacy and the current management and treatment of CE is still largely based on expert opinion and moderate to poor quality of evidence. 8, 11, 15, 19 Despite these limitations, standard of treatment in CE today, is based in the use of different surgical techniques with or without chemotherapy. Nevertheless, there are a high percentage of patients who are not suitable candidates for surgical treatment, and their treatment consists of other types of therapies such as PAIR, anthelmintics or 'watch and wait' strategy.
During two decades, the authors have attended to patients with CE without having a previously established treatment protocol in this hospital. The aim of this study was to determine the most frequently applied treatment in this cohort, the factors involved in the treatment selection and the complications regarding each type of treatment applied. Thus, more than 500 patients with CE in this hospital have been attended, with surgical treatment being the main treatment used. It was detected that factors such as age, co-morbidity or clinical setting were involved in selecting the type of treatment applied to the same patient and the highest comorbidity were the collective most frequently directed to an alternative treatment based on 'watch and wait' strategy. Other factors, as cyst stage, were not so important for choosing treatment. In fact, 134 patients with cysts type 4 and 5, which may be considered innactive cysts, had been operated on, since 140 patients with type 1, 2 and 3 cysts, which were active cysts, were operated on.
Besides, there is no experience in PAIR in this center, so patients that could be eligible for percutaneous treatment did not.
Regarding surgical methods, it was found that factors, such as the cyst location, size and number were involved. Therefore, the authors detected a higher proportion of surgical interventions in thoracic CE than in liver CE. These differences could be explained because thoracic CE is more frequently symptomatic than other locations. 20 However, a selection bias is also possible due to the fact that the Service of Thoracic Surgery involves a referral of several areas of health of other regions, from which many patients were referred for surgical procedure.
Other characteristics such as large size or a solitary CE were also factors associated with the use of a surgical procedure. In this sense, larger cysts are usually active cyst with a higher growth capacity and, consequently, a higher possibility of complication. Moreover, because of the high failure rate of treatment, multiples cyst in different locations are a classic factor that results in the patient not being recommended for surgical resection.
This work also detected that the anthelmintics used were somewhat associated with surgical treatment. Although there are studies that showed the utility of benzimidazole only as a treatment for CE patients with response rates ranging from 28.5% to 73%, there was a high relapse rate after the completion of treatment that limited its use. The use of combined benzimidazoles and praziquantel could be an alternative treatment; however, despite the safety 11 of this combination, their clinical use is not still well characterized. Thus, medical treatment for CE is usually limited to decrease the relapse after of surgical treatment.
Another aim of this work was to evaluate the complications associated with different types of treatment used. Between patients treated with surgical treatment, approximately 20% had surgical complications, with fistula being more frequent in the liver than in other locations, especially when CE was localized in the IV and VIII segments.
The mortality rate was similar to that observed in a multicenter series study (1-2%), which revealed a lesser postoperative V. Velasco-Tirado et al. Transactions of the Royal Society of Tropical Medicine and Hygiene morbidity. 21 However, other characteristics of the cysts or the patient's characteristics were not associated with an increasing risk of complications. A postoperative mortality rate of 2% was observed that was clearly associated with patient age and comorbidity. In this sense, defining the clinical exclusion criteria of surgical patients is important to decrease this mortality rate.
Regarding medical treatment, anthelmintics were typically used as a complementary treatment to surgical procedure. A low risk of complications was detected, with the most frequent being digestive intolerance and hypertransaminasemia; however, both cases were resolved after drug discontinuation.
Finally, another aim of this study was to examine the global and attributable mortality in the present cohort. The authors had previously published a study that examined the mortality and main causes of mortality in CE patients. In this previous study, only CE patients who died in this hospital (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) were evaluated, and thus, it was concluded that complications of CE were one of the main causes of mortality in patients infected by Echinococcus granulosus. However, due the methodology used in previous work, it could not be established whether other factors associated with patient mortality. In order to evaluate these factors, the present study included patients with CE (1998-2015) who had at least two evaluations in this hospital. Thus, similar to the authors' previous work, it was also detected that complications of CE were one of the most important causes of global mortality after cancer and cardiovascular diseases.
Moreover, another important objective in this study was to evaluate the factors associated with mortality in this cohort. Thus, thoracic CE and CE with large-sized or increased numbers of cysts were factors associated with higher mortality. Also, depending on the host, age and comorbidity were also associated with higher mortality. Finally, the authors also studied if the type of treatment could be involved with mortality. Therefore, watch and wait strategy was also associated with a higher mortality. The variables that most influence the mortality caused by CE in this cohort were the presence of comorbidity [Exp(B)=10.42; CI 95%, 1.22-88.59; p=0.032] and complications in the treatment. To current knowledge, there are no other studies that evaluate the factors involved with mortality in patients with CE.
Although this work has some limitations and bias due to the retrospective nature of the study, it is believed that this study can contribute to selecting the best treatment for patients with CE. However, future studies involving other multi-center randomized clinical trials could provide us with insight to develop treatments for cystic echinococcosis. Besides, control programs with dog deworming, stray dog culling, sheep and goat vaccination and education projects are required for facing this neglected disease.
Conclusions
Characteristics of cysts and patients are factors involved in the selection of different treatments for CE patients. Surgical complications were frequent, but were accompanied by a low mortality rate. Complications of CE are one of the most common causes of mortality in CE patients, with size, location, and number of cysts and 'watch and wait' treatment strategy being the main factors associated with mortality.
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